➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Medtronic
McKesson
Boehringer Ingelheim
Moodys

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,952,064


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,952,064 protect, and when does it expire?

Patent 8,952,064 protects ABSORICA and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,952,064
Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle
Inventor(s): Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Philippe (Uccle, BE)
Assignee: Galephar Pharmaceutical Research, Inc. (Humacao, PR)
Application Number:13/525,857
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,952,064
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,952,064

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 AB2 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 AB2 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-005 Aug 15, 2014 AB2 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 AB2 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-006 Aug 15, 2014 AB2 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-004 May 25, 2012 AB2 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,952,064

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/BE00/00111Sep 22, 2000
PCT/IB00/00163Sep 21, 2001

International Family Members for US Patent 8,952,064

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 270544 ⤷  Free Forever Trial
Australia 8943801 ⤷  Free Forever Trial
Brazil 102013032172 ⤷  Free Forever Trial
Canada 2423170 ⤷  Free Forever Trial
Canada 2836228 ⤷  Free Forever Trial
Germany 60104206 ⤷  Free Forever Trial
European Patent Office 1318791 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Colorcon
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.